Janet +61 411 816 444
PO Box 636 Bondi Junction NSW 1355
Australia
The LAM Australasia Research Alliance (LARA) is dedicated to improving the health prospects of women with LAM in Australia, New Zealand and throughout the region. A disease that affects only women, LAM is rare and often devastating.
ALL DONATIONS TO LARA ARE FULLY TAX DEDUCTIBLE
Your contribution to LARA will go 100% to funding vital medical research to find a cure for LAM.
You can donate to the LAM Australasia Research Alliance by sending us a cheque, using our PayPal facility, or by making a deposit directly to our ANZ Bank account: 012 055 4926 67193.
Please advise us of your donation by sending an email to admin@lara.org.au with your name, address and email address. We will respond with our thanks and a fully tax deductible receipt.
Major Donors
Macquarie Group Foundation
Roth Charitable Foundation
Mr Robert Gavshon
Hollick Wines
Acknowledgements
LARA thanks the professionals who work pro bono for this not-for-profit organisation. We highly recommend the services of:
Ben Higham, Webhead
Karen Riethmuller, KGR Design
Peter Hersh, Loggica Pty Ltd
Peter Kelso
|
Effects of Prolactin on TSC2-null Eker Rat Cells and in Pulmonary LAM
|
Effects of Prolactin on TSC2-null Eker Rat Cells and in Pulmonary Lymphangioleiomyomatosis (LAM)Terasaki Y, Yahiro K, Pacheco-Rodriguez G, Steagall WK, Stylianou MP, Evans JF, Walker AM, Moss J. Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States. AbstractRationaleLymphangioleiomyomatosis, a cystic lung disease of women, is characterized by proliferation of smooth muscle-like lymphangioleiomyomatosis cells, which possess mutations in the tuberous sclerosis complex genes, TSC1/TSC2. Growth factors involved in LAM cell proliferation are unknown. Prolactin, an important reproductive hormone in women, is known to promote cell proliferation and survival in other tissues. ObjectiveTo determine the role of prolactin on signaling and proliferation in lymphangioleiomyomatosis. MethodsProlactin levels in lymphangioleiomyomatosis patient sera were correlated with clinical status. Components of prolactin signal transduction pathways were assessed in lymphangioleiomyomatosis lesions from human lung explants by real time RT-PCR and immunohistochemistry. Prolactin effects on proliferation and signaling were quantified in tuberin-deficient and tuberin-expressing rat cells in vitro. Measurements and Main ResultsHigher prolactin levels in sera of lymphangioleiomyomatosis patients were associated with a faster rate of decline in FEV1 and an increased history of pneumothorax (P<0.01). Higher levels of prolactin and prolactin receptor mRNA and immunoreactivity were found in lymphangioleiomyomatosis lesions when compared with vascular smooth muscle cells in the same region of tissue. This was accompanied by evidence of activation of STAT1, STAT3, p44/42, and p38 MAPK. Tsc2-/- Eker rat embryonic fibroblasts expressed more prolactin receptor than did Tsc2+/+ cells, and responded to prolactin with increased proliferation and activation of the same signaling pathways seen in vivo. ConclusionsProlactin may be an important growth factor in the pathogenesis of lymphangioleiomyomatosis. PMID: 20413627 [PubMed - as supplied by publisher] |